Literature DB >> 18506846

Hypoxia-inducible factor 1 and cancer pathogenesis.

Gregg L Semenza1.   

Abstract

Hypoxia-inducible factor 1 (HIF-1) is a transcriptional activator that mediates adaptive responses to hypoxia. HIF-1 activity is increased in the majority of human cancers as a result of genetic alterations and intratumoral hypoxia. HIF-1 activates the transcription of genes that increase O(2) availability by stimulating angiogenesis or that reprogram cellular metabolism to adapt to reduced O(2) availability. Proof of principle studies in mouse models suggests that inhibition of HIF-1 activity may have therapeutic effects, especially in combination with other anticancer drugs. Copyright 2008 IUBMB

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18506846     DOI: 10.1002/iub.93

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  56 in total

Review 1.  Correlation of expression of hypoxia-related proteins with prognosis in oral squamous cell carcinoma patients.

Authors:  A W Eckert; M Kappler; J Schubert; H Taubert
Journal:  Oral Maxillofac Surg       Date:  2012-05-17

Review 2.  Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.

Authors:  Lara Milane; Shanthi Ganesh; Shruti Shah; Zhen-Feng Duan; Mansoor Amiji
Journal:  J Control Release       Date:  2011-04-08       Impact factor: 9.776

3.  Hypoxia elicits broad and systematic changes in protein subcellular localization.

Authors:  Robert Michael Henke; Ranita Ghosh Dastidar; Ajit Shah; Daniela Cadinu; Xiao Yao; Jagmohan Hooda; Li Zhang
Journal:  Am J Physiol Cell Physiol       Date:  2011-07-13       Impact factor: 4.249

Review 4.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

Review 5.  Mitochondria-mediated energy adaption in cancer: the H(+)-ATP synthase-geared switch of metabolism in human tumors.

Authors:  María Sánchez-Aragó; Laura Formentini; José M Cuezva
Journal:  Antioxid Redox Signal       Date:  2012-09-24       Impact factor: 8.401

6.  Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.

Authors:  Mohammad H Pourgholami; Zhao Y Cai; Samina Badar; Kiran Wangoo; Marianne S Poruchynsky; David L Morris
Journal:  BMC Cancer       Date:  2010-04-15       Impact factor: 4.430

7.  Effects of cellular iron deficiency on the formation of vascular endothelial growth factor and angiogenesis. Iron deficiency and angiogenesis.

Authors:  Jonathan Eckard; Jisen Dai; Jing Wu; Jinlong Jian; Qing Yang; Haobin Chen; Max Costa; Krystyna Frenkel; Xi Huang
Journal:  Cancer Cell Int       Date:  2010-08-19       Impact factor: 5.722

8.  HIF1alpha isoforms in benign and malignant prostate tissue and their correlation to neuroendocrine differentiation.

Authors:  Nastaran Monsef; Maria Soller; Ioannis Panagopoulos; Per Anders Abrahamsson
Journal:  BMC Cancer       Date:  2010-07-21       Impact factor: 4.430

9.  Transcription factor Sp1 induces ADAM17 and contributes to tumor cell invasiveness under hypoxia.

Authors:  Alexandra Szalad; Mark Katakowski; Xuguang Zheng; Feng Jiang; Michael Chopp
Journal:  J Exp Clin Cancer Res       Date:  2009-09-22

Review 10.  RNA-binding proteins implicated in the hypoxic response.

Authors:  Kiyoshi Masuda; Kotb Abdelmohsen; Myriam Gorospe
Journal:  J Cell Mol Med       Date:  2009-07-06       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.